Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer.
Catherine PhamFang NiuThomas DelateGary L BuchschacherYan LiEkim EkinciKim LeRita L HuiPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2023)
These findings suggest that bevacizumab-awwb is as effective and safe as bevacizumab reference product for the real-world treatment of mCRC.